Despite Misinformation War by Mainstream, Ivermectin Again Shows Antiviral Activity Against COVID-19, Reduces Transmission in “Int. Journal of Infectious Diseases” New Publication

Lazy eyes listen
  • They Lied, We Died!
  • There were lower viral loads and less viable cultures in the ivermectin group, which shows its anti-SARS-CoV-2 activity. It could reduce transmission in these patients and encourage further studies with this drug. – IJID

NewsRescue

We have severally in the past published on the scientific truth about repositioning Ivermectin as an option in the war against Covid. Our experts have expressed frustration at the unscientific campaign of calumny by mainstream governing agencies and media against this scientific option.

Misinformation

Quietly, the highest level journal on infectious diseases, so named, “the International Journal of Infectious Diseases” this July published one more study showing a positive role of Ivermectin , the global award winning drug as a preventative and therapeutic option against Covid-19.

Jessica Nye, PhD in Infectious Diseases Advisor summarizes from the study,

“Ivermectin was found to decrease the duration of viral shedding in patients with mild to moderate COVID-19 infection, suggesting its value as an anti-SARS-CoV-2 agent and potential to decrease COVID-19 transmission. These study findings were published in the International Journal of Infectious Diseases .

“Although more patients who received ivermectin tested negative for SARS-CoV-2 infection at days 4 through 10 compared with those who received placebo, this increase was significant only at days 6 (odds ratio [OR], 2.62; 95% CI, 1.09-6.31; P =.03) and 8 (OR, 3.32; 95% CI, 1.25-8.82; P =.01).

“Similar results were noted in the multivariable logistic regression analysis. At day 8 only, a significantly increased odds of testing negative for SARS-CoV-2 infection was observed among patients in the ivermectin vs placebo groups (adjusted OR, 3.70; 95%, 1.19-11.49; P =.02).

“This study was limited by its small sample size and its predominantly male population. In addition, treatment adherence among patients who received ivermectin was not confirmed by the researchers.

‘According to the researchers, “[this] study supports the notion that ivermectin has anti-SARS-CoV-2 activity.” They concluded, “if used at the early stage of disease onset, it may shorten the isolation time and reduce [COVID-19] transmission.”’